СПИСОК ЛИТЕРАТУРЫ

Поставить закладку

Шелыгин, Ю. А., Ивашкин, В. Т., Белоусова, Е. А., Решетов, И. В., Маев, И. В., Ачкасов, С. И. и др. Клинические рекомендации: Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10-44. – doi.org/10.33878/2073-7556-2023-22-1-10-44.
Ивашкин, В. Т., Шелыгин, Ю. А., Абдулганиева, Д. И., Абдулхаков, Р. А., Алексеева, О. П., Алексеенко, С. А. и др. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38. – doi.org/10.33878/2073-7556-2020-19-2-8-3.
Torres, J., Chaparro, M., Julsgaard, M., Katsanos, K., Zelinkova, Z., Agrawal, M. et al. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. Journal of Crohn's and Colitis. 2023;17(1):1-27. – doi.org/10.1093/ecco-jcc/jjac115.
Успенская, Ю. Б. Воспалительные заболевания кишечника и беременность: научно-практическая монография. – М. : Прима Принт, 2015. – 40 с.
Успенская, Ю. Б. Воспалительные заболевания кишечника у женщин репродуктивного возраста: дис. … канд. мед. наук. – М., 2007.
Roseira, J., Magro, F., Fernandes, S. et al. Sexual quality of life in inflammatory bowel disease: a multicenter, national-level study. Inflamm Bowel Dis. 2020;26:746–55. – doi:10.1093/ibd/izz185.
Ghosh, S., Mitchell, R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations [EFCCA] patient survey. J Crohns Colitis. 2007;1:10–20. – doi:10.1016/j.crohns.2007.06.005.
Blackburn, W. D., Alarcón, G. S. Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1989;32:1341–2. – doi:10.1002/anr.1780321029.
Reland, A., Jewell, D. P. Sulfasalazine-induced impotence: a beneficial resolution with olsalazine? // J Clin Gastroenterol. 1989; 11:711.
FSRH Guideline Sexual and Reproductive Health for Individuals with Inflammatory Bowel Disease. 2016.
Orholm, M., Munkholm, P., Langholz E. et al. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324:84–8. – doi:10.1056/nejm199101103240203.
Joossens, M., Van Steen, K., Branche, J. et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn’s disease. Inflamm Bowel Dis. 2010;16:58–67. – doi:10.1002/ibd.20985.
Laharie, D., Debeugny, S., Peeters, M. et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001;120:816–9. – doi:10.1053/gast.2001.22574.
Bischoff, S., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S. et al. ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clinical nutrition. 2020;39(3):632–653. – doi.org/10.1016/j.clnu.2019.11.002.
Bengtson, M. B., Aamodt, G., Mahadevan, U. et al. Inadequate gestational weight gain, the hidden link between maternal IBD and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Inflamm Bowel Dis. 2017;23:1225–33. – doi:10.1097/mib.0000000000001123.
Bengtson, M. B., Martin, C. F., Aamodt, G. et al. Inadequate gestational weight gain predicts adverse pregnancy outcomes in mothers with inflammatory bowel disease: results from a prospective US pregnancy cohort. Dig Dis Sci. 2017;62:2063–9. – doi:10.1007/s10620-017-4547-5.
Mahadevan, U., Robinson, C., Bernasko, N. et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. Gastroenterology. 2019;156:1508– 24. – doi:10.1053/j.gastro.2018.12.022.
Abhyankar, A., Ham, M., Moss, A. C. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:460–6. – doi:10.1111/apt.12417.
Tavernier, N., Fumery, M., Peyrin-Biroulet, L. et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:847– 53. – doi:10.1111/apt.12478.
Abdul Sultan, A., West, J., Ban, L., Humes, D., Tata, L. J., Fleming, K. M. et al. Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease: A Population-Based Study from England. Inflamm Bowel Dis. 2016 Jul;22(7):1621-30.
Ban, L., Tata, L. J., Humes, D. J. et al. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther. 2015;42:855–66. – doi:10.1111/apt.13354.
Ananthakrishnan, A. N., Martin, C., Kane, S. et al. Paternal disease activity is associated with difficulty in conception among men with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:203–4. – doi:10.1016/j.cgh.2018.04.001.
Banerjee, A., Scarpa, M., Pathak, S. et al. Inflammatory bowel disease therapies adversely affect fertility in men: a systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets. 2019;19:959–74. – doi:10.2174/1871530319666190313112110.
Simsek, M., Lambalk, C. B., Wilschut, J. A. et al. The associations of thiopurines with male fertility and paternally exposed offspring: a systematic review and meta-analysis. Hum Reprod Update. 2018;24:192–206. – doi:10.1093/humupd/dmx034.
Ley, D., Jones, J., Parrish, J. et al. Methotrexate reduces DNA integrity in sperm from men with inflammatory bowel disease. Gastroenterology. 2018;154:2064–7.e3. – doi:10.1053/j.gastro.2018.02.025.
Grosen, A., Bellaguarda, E., Nersting, J. et al. Low-dose methotrexate therapy does not affect semen parameters and sperm DNA. Inflamm Bowel Dis. 2021. – doi:10.1093/ibd/izab205.
Lee, S., Crowe, M., Seow, C. H. et al. The impact of surgical therapies for inflammatory bowel disease on female fertility. Cochrane Database Syst Rev. 2019;7:CD012711. – doi:10.1002/14651858.CD012711.pub2.
Rajaratnam, S. G., Eglinton, T. W., Hider, P. et al. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int J Colorectal Dis. 2011; 26:1365–74. – doi:10.1007/s00384-011-1274-9.
Johnson, P., Richard, C., Ravid, A. et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2004;47:1119–26. – doi:10.1007/s10350-004-0570-7.
Pachler, F. R., Bisgaard, T., Mark-Christensen, A. et al. Impact on fertility after failure of restorative proctocolectomy in men and women with ulcerative colitis: a 17-year cohort study. Dis Colon Rectum. 2020; 63:816–22. – doi:10.1097/DCR.0000000000001640.
Oza, S. S., Pabby, V., Dodge, L. E. et al. Factors associated with the success of in vitro fertilization in women with inflammatory bowel disease. Dig Dis Sci. 2016; 61:2381–8. – doi:10.1007/s10620-016-4076-7.
Nørgård, B. M., Larsen, P. V., Fedder, J. et al. Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn’s disease receiving assisted reproduction: a 20-year nationwide cohort study. Gut. 2016; 65:767–76. – doi:10.1136/gutjnl-2015-311246.
Pachler, F. R., Toft, G., Bisgaard, T. et al. Use and success of in vitro fertilisation following restorative proctocolectomy and ileal pouch-anal anastomosis. A nationwide 17-year cohort study. J Crohns Colitis. 2019; 13:1283–6. – doi:10.1093/ecco-jcc/jjz055.
Vigod, S. N., Kurdyak, P., Brown, H. K. et al. Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut. 2019; 68:1597–605. – doi:10.1136/gutjnl-2018-317610.
Tandon, P., Leung, K., Yusuf ,A. et al. Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy: a systematic review. J Clin Gastroenterol. 2019;53:574–81. – doi:10.1097/MCG.0000000000001244.
Klajnbard, A., Szecsi, P. B., Colov, N. P. et al. Laboratory reference intervals during pregnancy, delivery and the early postpartum period. Clin Chem Lab Med. 2010;48:237– 48. – doi:10.1515/CCLM.2010.033.
Uspenskaya, Y. B., Belogubova, S. J. Diagnostic possibilities of fecal calprotectin application in patients with inflammatory bowel diseases during pregnancy (literature review and clinical observations). Koloproktologia. 2018;(2):95-101. – doi.org/10.33878/2073-7556-2018-0-2-95-101. (In Russ.)
Ludvigsson, J. F., Lebwohl, B., Ekbom, A. et al. Outcomes of pregnancies for women undergoing endoscopy while they were pregnant: a nationwide cohort study. Gastroenterology. 2017;152:554–63 e559. – doi:10.1053/j.gastro.2016.10.016.
Bates, S. M., Rajasekhar, A., Middeldorp, S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317–59. – doi:10.1182/bloodadvances.2018024802.
Hansen, A. T., Erichsen, R., Horváth-Puhó, E. et al. Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period. J Thromb Haemost. 2017;15:702–8. – doi:10.1111/jth.13638.
Kim, Y. H., Pfaller, B., Marson, A. et al. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: A systematic review and meta-analysis. Medicine. 2019;98:17309. – doi:10.1097/MD.0000000000017309.
Killeen, S., Gunn, J., Hartley, J. Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy. Colorectal Dis. 2017;19:123– 38. – doi:10.1111/codi.13413.
Germain, A., Chateau, T., Beyer-Berjot, L. et al. Surgery for Crohn’s disease during pregnancy: A nationwide survey. United Eur Gastroenterol J. 2020;8:736–40. – doi:10.1177/2050640620921060.
Rasmussen, A. S., Christiansen, C. F., Ulrichsen, S. P. et al. Non-obstetric abdominal surgery during pregnancy and birth outcomes: a Danish registry-based cohort study. Acta Obstet Gynecol Scand. 2020;99:469–76. – doi:10.1111/aogs.13775.
Cornish, J., Tan, E., Teare, J. et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830–7. – doi:10.1136/gut.2006.108324.
Gionchetti, P., Dignass, A., Danese, S. et al. Third European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016. Part 2: surgical management and special situations. J Crohns Colitis. 2017; 11:135–49. – doi:10.1093/ecco-jcc/jjw169.
Серова, В. Н., Сухих, Г. Т. Клинические рекомендации. Акушерство и гинекология. – ГЭОТАР-Медиа. 2014;4:1024.
Sheehy, O., Santos, F., Ferreira, E. et al. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf. 2015;10:170–9. – doi:10.2174/157488631002150515124548.
Medication Guidelines For Obstetrics and Gynaecology. Antimicrobial safety In Pregnancy and Lactation. HSE Clinical Programme in Obstetrics and Gynaecology. 2017; 2(1):10-69.
Yefet, E., Schwartz, N., Chazan, B. et al. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG. 2018; 125:1069–76. – doi:10.1111/1471-0528.15119.
Hviid, A, Molgaard-Nielsen, D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183:796–804. – doi:10.1503/cmaj.101063.
Homar, V, Grosek, S, Battelino, T. High-dose methylprednisolone in a pregnant woman with Crohn’s disease and adrenal suppression in her newborn. Neonatology 2008;94:306–9. – doi:10.1159/000151652.
Odufalu, F. D., Long, M., Lin, K. et al. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut. 2022;71(9):1766–1772. – doi:10.1136/gutjnl-2021-325317.
Cleary, B. J., Kallen, B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85:647–54. – doi:10.1002/bdra.20583
Hutson, J. R., Matlow, J. N., Moretti, M. E., Koren, G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013 Jan;33(1):1-8. – doi: 10.3109/01443615.2012.716106.
Flanagan, E. et al. Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Alimentary Pharmacology & Therapeutics. 2021;53(7):810-820.
Kozlowski, R. D., Steinbrunner, J. V., MacKenzie, A. H. et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990; 88:589–92. – doi:10.1016/0002-9343[90]90522-f.
Julsgaard, M., Christensen, L. A., Gibson, P. R. et al. Concentrations of Adalimumab and Infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110–9. – doi:10.1053/j.gastro.2016.04.002
Mahadevan, U., Vermeire, S., Lasch, K. et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017; 45:941–50. – doi:10.1111/apt.13960.
Wils, P., Seksik, P., Stefanescu, C. et al. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther. 2021;53:460–70. – doi:10.1111/apt.16192.
Mahadevan, U. et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Am J Obstet Gynecol. 2019 Apr;220(4):308-323. – doi: 10.1016/j.ajog.2019.02.027.
Julsgaard, M., Nørgaard, M., Hvas, C. L. et al. Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn’s disease. Scand J Gastroenterol. 2014;49:958–66. – doi:10.3109/00365521.2014.920913.
Yu, A., Friedman, S., Ananthakrishnan, A. N. Incidence and predictors of flares in the postpartum year among women with inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:1926–32. – doi:10.1093/ibd/izz313.
Malhi, G., Tandon, P., Perlmutter, J. W. et al. Risk factors for postpartum disease activity in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2021. – doi:10.1093/ibd/izab206.
Matro, R., Martin, C. F., Wolf, D. et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155:696–704. – doi:10.1053/j.gastro.2018.05.040.
de Lima, A., Zelinkova, Z., van der Ent, C. et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261–8. – doi:10.1136/gutjnl-2015-309321.
Duricova, D., Dvorakova, E., Hradsky, O. et al. Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis. 2019;25:789–96. – doi:10.1093/ibd/izy294.
Beaulieu, D. B., Ananthakrishnan, A. N., Martin, C. et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16:99–105. – doi:10.1016/j.cgh.2017.08.041.
Wieringa, J. W., van Beek, R. H. T., Rövekamp, L. W. et al. Response to vaccination in infants exposed to antitumor necrosis factor alpha In Utero. Pediatr Infect Dis J. 2021;40:912–6. – doi:10.1097/inf.0000000000003271.
Goulden, B., Chua, N., Parker, E. et al. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatology. 2022. – doi:10.1093/rheumatology/keac141.
Nelis, G. F. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;1:383. – doi:10.1016/s0140-6736[89]91754-6.
Esbjörner, E., Järnerot, G., Wranne, L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987;76:137–42. – doi:10.1111/j.1651-2227.1987.tb10430.x.
Ost, L., Wettrell, G., Björkhem, I. et al. Prednisolone excretion in human milk. J Pediatr. 1985;106:1008–11. – doi:10.1016/s0022-3476[85]80259-6.
Christensen, L. A., Dahlerup, J. F., Nielsen, M. J. et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28:1209–13. – doi:10.1111/j.1365-2036.2008.03843.x.
Julsgaard, M., Baumgart, D. C., Baunwall, S. M. et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther. 2021;54:1320–9. – doi:10.1111/apt.16593.
Johns, D. G., Rutherford, L. D., Leighton, P. C. et al. Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112:978–80. – doi:10.1016/0002-9378[72]90824-1.
Tang, C., Li, Y., Lin, X. et al. Prolactin increases tumor necrosis factor alpha expression in peripheral CD14 monocytes of patients with rheumatoid arthritis. Cell Immunol. 2014;290:164–8. – doi:10.1016/j.cellimm.2014.06.005.
Mañosa, M., Navarro-Llavat, M., Marín, L. et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol. 2013;48:427–32. – doi:10.3109/00365521.2013.772229.
Baron, S., Turck, D., Leplat, C. et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut. 2005;54:357– 63. – doi:10.1136/gut.2004.054353.
Güngör, D., Nadaud, P., Dreibelbis, C. et al. Infant milk-feeding practices and diagnosed celiac disease and inflammatory bowel disease in offspring: a systematic review. Am J Clin Nutr. 2019;109:838s–51s. – doi:10.1093/ajcn/nqy371.
Nader D Daoud, Hassan Ghoz et al. Oral Contraceptive Pills Are an Effective Method of Preventing Pregnancy in Women With Crohn’s Disease, Crohn's & Colitis 360, Volume 4, Issue 1, 01.2022, otab078. – doi.org/10.1093/crocol/otab078.
Zapata, L. B., Paulen, M. E., Cansino, C. et al. Contraceptive use among women with inflammatory bowel disease: a systematic review. Contraception 2010; 82:72–85. – doi:10.1016/j.contraception.2010.02.012.
Chaparro, M., Kunovský, L., Aguas, M. et al. Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes from an ECCO CONFER Multicentre Case Series [Scar Study]. J Crohns Colitis 2022. – doi:10.1093/ecco-jcc/jjac050.
Nassan, F. L., Coull, B. A., Skakkebaek, N. E. et al. A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. Environ Int 2016; 95:120–30. – doi:10.1016/j.envint.2016.08.006.
Ветчанина, Е. Г. Психологические состояния беременных женщин в условиях острого и хронического стресса и особенности их психокоррекции: автореф. дис. … канд. психол. наук. – М., 2003. – 24 с.
Liu, X, Wang, S, Wang, G. Prevalence and Risk Factors of Postpartum Depression in Women: A Systematic Review and Meta-analysis. J Clin Nurs. 2022 Oct;31(19-20):2665-2677. – doi: 10.1111/jocn.16121. Epub 2021 Nov 8. PMID: 34750904.
Ghaedrahmati, M., Kazemi, A., Kheirabadi, G., Ebrahimi, A., Bahrami, M. Postpartum depression risk factors: A narrative review. J Educ Health Promot. 2017 Aug 9;6:60. – doi: 10.4103/jehp.jehp_9_16. PMID: 28852652.
Клинические рекомендации. Преэклампсия, эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде 2021 г.
ACOG. Hypertension in pregnancy. Task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122–1131. DOI: 10.1097/01.aog.0000437382.03963.88.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница